Pazopanib: A novel multitargeted tyrosine kinase inhibitor

[1]  R. Figlin,et al.  Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) , 2006 .

[2]  G. Tonon,et al.  In vitro and in vivo activity of the VEGF receptor inhibitor PAZOPANIB (GW786034) in Multiple Myeloma: Therapeutic implications. , 2006 .

[3]  R. Bukowski,et al.  A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. , 2006, Clinical genitourinary cancer.

[4]  C. Miller,et al.  Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice , 2005 .

[5]  R. Bukowski,et al.  Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .

[6]  H. Hurwitz,et al.  Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors , 2005 .

[7]  E. Small,et al.  Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Tassone,et al.  Effects of the indazolylpyrimidine GW786034 on angiogenesis and MM cell growth: Therapeutic implications. , 2004 .

[9]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[10]  H. Hurwitz,et al.  Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[12]  C. Arteaga.  Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs? , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[14]  J. Adams,et al.  A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. , 2002, Current opinion in chemical biology.

[15]  M. Fraley,et al.  Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents , 2002, Expert opinion on investigational drugs.

[16]  P. Renhowe.  Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress. , 2002, Current opinion in drug discovery & development.

[17]  G. Demetri.  Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. , 2001, Seminars in oncology.

[18]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[19]  B R Johansson,et al.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.

[20]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[21]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  S. Hubbard,et al.  Protein tyrosine kinase structure and function. , 2000, Annual review of biochemistry.

[23]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[24]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.